Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its
incidence is still increasing. While the primary curative treatment for HCC is surgical …

Hepatocellular carcinoma (HCC) is characterized as a highly chemoresistant cancer with no
effective systemic therapy. Despite surgical or locoregional therapies, prognosis remains …

Hepatocellular carcinoma (HCC) is a major health problem. Mortality owing to liver cancer
has increased in the past 20 years, with recent studies reporting an incidence of 780,000 …

Hepatocellular carcinoma (HCC) remains a highly complex disease resistant to commonly
used chemotherapy and radiotherapy. As the sixth most common cancer worldwide with the …

In recent years, molecular-targeted agents have been used clinically to treat various
malignant tumors. In May 2009, sorafenib (Nexavar®) was approved in Japan for …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer related
mortality worldwide. The incidence of HCC has been increasing annually. Viral infection …

Hepatocellular carcinoma (HCC) can be lethal due to its aggressive course and lack of
effective systemic therapies for advanced disease. Sorafenib is the only systemic therapy …

Hepatocellular carcinoma (HCC) is one of the most frequent tumors worldwide. The majority
of HCC cases occur in patients with chronic liver disease. Despite regular surveillance to …

Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis and worldwide
rising incidence during the last years. Although orthotopic liver transplantation, surgical …